Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2010-03-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.00135-10PMID 20308381PMCID PMC2876368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

  2010cited by this paper
• 86 SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS

  2009cited by this paper
• 4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

  2009cited by this paper
• MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease

  2009cited by this paper
• New hope for a cure for chronic hepatitis C.

  2009cited by this paper
• Towards the non-invasive diagnosis of cirrhosis: the nuts-cirrhosis connection.

  2009cited by this paper
• Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior.

  2009cited by this paper
• Characterization of resistance mutations against HCV ketoamide protease inhibitors.

  2008cited by this paper
• Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

  2007cited by this paper
• SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.

  2007cited by this paper
• Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

  2007cited by this paper
• SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

  2006cited by this paper
• Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.

  2006cited by this paper
• Computational Study of the Effects of Mutations A156T, D168V, and D168Q on the Binding of HCV Protease Inhibitors.

  2006cited by this paper
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

  2006cited by this paper
• Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

  2006influential reference
• The behavior and significance of slow-binding enzyme inhibitors.

  2006cited by this paper
• Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

  2004cited by this paper
• In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

  2003cited by this paper
• 972 VX-950: the discovery of an inhibitor of the hepatitis C NS3·4A protease and a potential hepatitis C virus therapeutic

  2003cited by this paper
• Synergy, antagonism, and what the chequerboard puts between them.

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity

  2001cited by this paper
• Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties.

  2000cited by this paper
• Hepatitis C Virus-Encoded Enzymatic Activities and Conserved RNA Elements in the 3′ Nontranslated Region Are Essential for Virus Replication In Vivo

  2000cited by this paper
• A continuous spectrophotometric assay for the hepatitis C virus serine protease.

  1999cited by this paper
• Construction, expression, and characterization of a novel fully activated recombinant single‐chain hepatitis C virus protease

  1998cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis.

  2023cites this paper
• Inhibitors of SARS-CoV-2 main protease: Biological efficacy and toxicity aspects.

  2023cites this paper
• The Q41R mutation in the HCV-protease enhances the reactivity towards MAVS by suppressing non-reactive pathways.

  2022cites this paper
• Viral proteases as therapeutic targets

  2022cites this paper
• Curing Hepatitis C with Direct‐Acting Antiviral Therapy

  2021cites this paper
• A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease

  2020cites this paper
• [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

  2019cites this paper
• Evolution of HCV NS3/4a Protease Inhibitors

  2019cites this paper
• Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors

  2019cites this paper
• Therapeutic effects of pegylated-interferon-α2a in a mouse model of multiple sclerosis

  2018cites this paper
• Synthetic Approaches to New Drugs Approved During 2016.

  2018cites this paper
• Discovery of Boceprevir and Narlaprevir: Ketoamide-Derived HCV NS3 Serine Protease Inhibitors for the Treatment of Chronic Hepatitis C

  2017cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis

  2016cites this paper
• Protease inhibitors‐based therapy induces acquired spherocytic‐like anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients

  2016cites this paper
• Design, synthesis, structure information and biochemical activity of new floro substituted organotin(IV) carboxylates.

  2016cites this paper
• Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.

  2016cites this paper
• Understanding Drug Resistance and Antibody Neutralization Escape in Antivirals: A Dissertation

  2016cites this paper
• New Drug Review Boceprevir: A Protease Inhibitor for the Treatment of Hepatitis C

  2015influential citation
• Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease

  2014cites this paper
• The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.

  2014cites this paper
• A New Stochastic Model for Subgenomic Hepatitis C Virus Replication Considers Drug Resistant Mutants

  2014influential citation
• Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.

  2014cites this paper
• Treatment of HCV infection with the novel NS3/4A protease inhibitors.

  2014cites this paper
• HCV-targeted antivirals: current status and future challenges.

  2014cites this paper
• Replication of the subgenomic hepatitis C virus replicon in the presence of the NS3 protease inhibitors: a stochastic model

  2013cites this paper
• COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT

  2013cites this paper
• Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor

  2013cites this paper
• Chapter 688 – Hepacivirin

  2013cites this paper
• Supplementary Material and Methods

  2012cites this paper
• Pharmacokinetic / Pharmacodynamic Predictors of Clinical Potency for 1 Hepatitis C Non-Nucleoside Polymerase and Protease Inhibitors 2 3

  2012cites this paper
• Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients

  2012cites this paper
• Discovery of Boceprevir and Narlaprevir: The First and Second Generation of HCV NS3 Protease Inhibitors

  2012cites this paper
• Mutations and the Development of Anti-viral Resistance

  2012cites this paper
• Targeted Covalent Enzyme Inhibitors

  2012cites this paper
• The race for interferon‐free HCV therapies: a snapshot by the spring of 2012

  2012cites this paper
• Viral proteases as targets for drug design.

  2012cites this paper
• Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

  2012cites this paper
• Boceprevir: a protease inhibitor for the treatment of hepatitis C.

  2012cites this paper
• New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

  2012cites this paper
• HCV protease inhibitors: using the evidence to guide clinical practice

  2012cites this paper
• Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.

  2011cites this paper
• Small Molecule Pan-Dengue and West Nile Virus NS3 Protease Inhibitors

  2011cites this paper
• Recent Progress in the Development of HCV Protease Inhibitors

  2011cites this paper
• Mechanisms of Substrate Recognition by HCV NS3/4A Protease Provide Insights Into Drug Resistance: A Dissertation

  2011cites this paper
• Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative.

  2011cites this paper
• Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.

  2011cites this paper
• Mechanisms of non-response to antiviral treatment in chronic hepatitis C.

  2011cites this paper
• Evolving drug therapies for chronic hepatitis C: Immunomodulation and beyond

  2011cites this paper
• Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

  2010cites this paper
• Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

  2010cites this paper
• Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

  2010cites this paper